ArticleLeukemia2015

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.

J Flynn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.